Skip to main content

Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris

Abstract

Androgenetic alopecia (AGA) and acne vulgaris are two conditions commonly seen by dermatologists. Androgens and the androgen receptors play an essential role in the manifestation of both conditions, and some systemic therapies function by interfering in this pathway. The use of topical antiandrogen therapies has gained traction in recent years due to their potential efficacy in treating AGA and acne vulgaris, as well as their reduced adverse effects compared with systemic drugs. This review discusses the role of androgens in skin physiology and pathology and assesses the potential efficacy and safety of three topical antiandrogen therapies in the treatment of AGA and acne vulgaris. A literature review utilizing the PubMed, US Clinical Trials, and SCOPUS databases was conducted to search for randomized clinical trials, systematic reviews, cohort studies, case reports, and other relevant published studies on the pathogenesis and treatment of each condition with topical finasteride, ketoconazole shampoo, and cortexolone 17α-propionate (C17P). The results demonstrated that topical formulations of finasteride, ketoconazole, and C17P are promising treatments for male pattern hair loss, especially topical finasteride in combination with topical minoxidil. Limited studies have shown C17P to have potential in treating acne vulgaris in both males and females. Minimal adverse effects have been reported in clinical trials for all topical therapies, although topical finasteride is still contraindicated in pregnancy. Recognizing the preliminary evidence, more peer-reviewed studies on topical antiandrogen treatments for AGA and acne vulgaris are necessary before definitive recommendations can be made regarding efficacy and safety. There is also a critical need to include more women in study populations for these treatments.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Randall VA. Androgens and human hair growth. Clin Endocrinol (Oxf). 1994;40(4):439–57.

    CAS  PubMed  Google Scholar 

  2. 2.

    Zouboulis CC, Degitz K. Androgen action on human skin: from basic research to clinical significance. Exp Dermatol. 2004;13(Suppl 4):5–10.

    CAS  PubMed  Google Scholar 

  3. 3.

    Lai J-J, Chang P, Lai K-P, Chen L, Chang C. The role of androgen and androgen receptor in the skin-related disorders. Arch Dermatol Res. 2012;304(7):499–510.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Zouboulis CC. Human skin: an independent peripheral endocrine organ. Horm Res. 2000;54(5–6):230–42.

    CAS  PubMed  Google Scholar 

  5. 5.

    Zouboulis CC, Chen W-C, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res. 2007;39(2):85–95.

    CAS  PubMed  Google Scholar 

  6. 6.

    Liang T, Hoyer S, Yu R, et al. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol. 1993;100(5):663–6.

    CAS  PubMed  Google Scholar 

  7. 7.

    Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28(7):778–808.

    CAS  PubMed  Google Scholar 

  8. 8.

    Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO, Boersma WJ. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol. 1992;133(3):467–75.

    CAS  PubMed  Google Scholar 

  9. 9.

    Chen W, Zouboulis CC, Orfanos CE. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatol Basel Switz. 1996;193(3):177–84.

    CAS  Google Scholar 

  10. 10.

    Picardo M, Ottaviani M, Camera E, Mastrofrancesco A. Sebaceous gland lipids. Dermatoendocrinol. 2009;1(2):68–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Zouboulis CC, Baron JM, Böhm M, et al. Frontiers in sebaceous gland biology and pathology. Exp Dermatol. 2008;17(6):542–51.

    CAS  PubMed  Google Scholar 

  12. 12.

    Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol. 2011;3(1):41–9.

    PubMed  PubMed Central  Google Scholar 

  13. 13.

    Knor T. The pathogenesis of acne. Acta Dermatovenerol Croat. 2005;13(1):44–9.

    PubMed  Google Scholar 

  14. 14.

    Dréno B, Pécastaings S, Corvec S, Veraldi S, Khammari A, Roques C. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32(S2):5–14.

    PubMed  Google Scholar 

  15. 15.

    Stewart ME. Sebaceous gland lipids. Semin Dermatol. 1992;11(2):100–5.

    CAS  PubMed  Google Scholar 

  16. 16.

    Downing DT, Stewart ME, Wertz PW, Strauss JS. Essential fatty acids and acne. J Am Acad Dermatol. 1986;14(2 Pt 1):221–5.

    CAS  PubMed  Google Scholar 

  17. 17.

    Sansone G, Reisner RM. Differential rates of conversion of testosterone to dihydrotestosterone in acne and in normal human skin: a possible pathogenic factor in acne. J Invest Dermatol. 1971;56(5):366–72.

    CAS  PubMed  Google Scholar 

  18. 18.

    Lookingbill DP, Horton R, Demers LM, Egan N, Marks JG, Santen RJ. Tissue production of androgens in women with acne. J Am Acad Dermatol. 1985;12(3):481–7.

    CAS  PubMed  Google Scholar 

  19. 19.

    Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21(5):314–28.

    PubMed  Google Scholar 

  20. 20.

    Sawers RA, Randall VA, Iqbal MJ. Studies on the clinical and endocrine aspects of antiandrogens. In: Jeffcoate SL, editor. Androgens and antiandrogen therapy. Current topics in endocrinology, vol. 1. Chichester: John Wiley; 1982. p. 145–68.

    Google Scholar 

  21. 21.

    Reynolds EL. The appearance of adult patterns of body hair in man. Ann N Y Acad Sci. 1951;53(3):576–84.

    CAS  PubMed  Google Scholar 

  22. 22.

    Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951;53(3):708–28.

    CAS  PubMed  Google Scholar 

  23. 23.

    Orentreich N, Durr NP. Biology of scalp hair growth. Clin Plast Surg. 1982;9(2):197–205.

    CAS  PubMed  Google Scholar 

  24. 24.

    Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291–303.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol. 1998;110(6):849–53.

    CAS  PubMed  Google Scholar 

  26. 26.

    Otberg N, Shapiro J. Chapter 88. Hair Growth Disorders. Fitzpatrick’s Dermatology in General Medicine. 8th ed. Access Medicine, McGraw-Hill Medical. New York, NY: The McGraw-Hill Companies; 2012. https://accessmedicine-mhmedical-com.ezp-prod1.hul.harvard.edu/Content.aspx?bookId=392&sectionId=41138795. Accessed 6 Sep 2018.

  27. 27.

    Olsen EA. Disorders of hair growth: diagnosis and treatment. 2nd ed. New York: McGraw-Hill, Medical Publishing Division; 2003.

    Google Scholar 

  28. 28.

    Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest. 1993;92(2):903–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3):296–300.

    CAS  PubMed  Google Scholar 

  30. 30.

    Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know: Update on androgenetic alopecia. Australas J Dermatol. 2011;52(2):81–8.

    PubMed  Google Scholar 

  31. 31.

    Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301–11.

    PubMed  Google Scholar 

  32. 32.

    Fabbrocini G, Cantelli M, Masarà A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018;4(4):203–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136–141.e5.

    PubMed  Google Scholar 

  34. 34.

    Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768–76.

    CAS  PubMed  Google Scholar 

  35. 35.

    Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91–5.

    PubMed  Google Scholar 

  36. 36.

    Hu AC, Chapman LW, Mesinkovska NA. The efficacy and use of finasteride in women: a systematic review. Int J Dermatol. 2019;58(7):759–76.

    PubMed  Google Scholar 

  37. 37.

    Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457–63.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19–27.

    CAS  PubMed  Google Scholar 

  39. 39.

    US Food and Drug Administration: Drug Databases. PROPECIA® (finasteride) Tablets, 1 mg drug insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788s018lbl.pdf.

  40. 40.

    Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842–9.

    CAS  PubMed  Google Scholar 

  41. 41.

    Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257–63.

    CAS  PubMed  Google Scholar 

  42. 42.

    Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147–53.

    PubMed  Google Scholar 

  43. 43.

    Mazzarella GF, Loconsole GF, Cammisa GA, Mastrolonardo GM, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatol Treat. 1997;8(3):189–92.

    Google Scholar 

  44. 44.

    Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75(1):47–51.

    PubMed  Google Scholar 

  45. 45.

    Chandrashekar BS, Nandhini T, Vasanth V, Sriram R, Navale S. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312–6.

    PubMed  Google Scholar 

  47. 47.

    Finasteride Treatment of Severe Nodulocystic Acne (NCT02502669). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02502669. Accessed 4 Jul 2019

  48. 48.

    Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474–7.

    PubMed  Google Scholar 

  49. 49.

    Debruyne FM, Witjes FA. Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer. Prog Clin Biol Res. 1987;243A:301–13.

    CAS  PubMed  Google Scholar 

  50. 50.

    Hugo Perez BS. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses. 2004;62(1):112–5.

    CAS  PubMed  Google Scholar 

  51. 51.

    Ayub M, Levell MJ. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins. J Steroid Biochem. 1989;33(2):251–5.

    CAS  PubMed  Google Scholar 

  52. 52.

    Eil C. Ketoconazole binds to the human androgen receptor. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 1992;24(8):367–70.

    CAS  Google Scholar 

  53. 53.

    NIZORAL® (KETOCONAZOLE) 2% SHAMPOO package insert from Janssen Pharmaceuticals. October 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019927s032lbl.pdf.

  54. 54.

    Ghetti P, Patrone P, Tosti A. Ketoconazole in the Treatment of Acne in Women. Arch Dermatol. 1986;122(6):629–629.

    CAS  PubMed  Google Scholar 

  55. 55.

    Vidal-Puig AJ, Muñoz-Torres M, Jódar-Gimeno E, et al. Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol. 1994;130(4):333–8.

    CAS  PubMed  Google Scholar 

  56. 56.

    Venturoli S, Fabbri R, Dal Prato L, et al. Ketoconazole therapy for women with acne and/or hirsutism. J Clin Endocrinol Metab. 1990;71(2):335–9.

    CAS  PubMed  Google Scholar 

  57. 57.

    Unno M, Cho O, Sugita T. Inhibition of Propionibacterium acnes lipase activity by the antifungal agent ketoconazole. Microbiol Immunol. 2017;61(1):42–4.

    CAS  PubMed  Google Scholar 

  58. 58.

    Akaza N, Akamatsu H, Numata S, et al. Microorganisms inhabiting follicular contents of facial acne are not only Propionibacterium but also Malassezia spp. J Dermatol. 2016;43(8):906–11.

    PubMed  Google Scholar 

  59. 59.

    Cassiopea Announces Very Positive Phase II Twelve Months Results for Breezula® (Clascoterone) in Treating Androgenetic Alopecia. Cassiopea. 16 Apr 2019. http://www.cassiopea.com/news-and-media/press-releases/yr-2019/190416.aspx. Accessed 5 Jul 2019.

  60. 60.

    Cassiopea Announces Positive Results from Phase III Acne Open-Label Safety Study Evaluating Winlevi® (Clascoterone) Topical Cream for Treatment up to 1 Year. Cassiopea. 26 Mar 2019. http://www.cassiopea.com/news-and-media/press-releases/yr-2019/190326.aspx. Accessed 5 Jul 2019.

  61. 61.

    Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412–8.

    CAS  PubMed  Google Scholar 

  62. 62.

    Rosette C, Rosette N, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol. 2019;18(2):197–201.

    PubMed  Google Scholar 

  63. 63.

    Mazzetti A, Moro L, Gerloni M, Cartwright M. A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects With facial acne. J Drugs Dermatol. 2019;18(6):570.

    CAS  PubMed  Google Scholar 

  64. 64.

    Cassiopea announces attainment of all primary and secondary endpoints and highly satisfactory safety data in its Phase 3 for Winlevi (Clascoterone) cream in Treating Acne. Cassiopea. 18 Oct 2018. http://www.cassiopea.com/news-and-media/press-releases/yr-2018/181018.aspx. Accessed 5 Jul 2019.

  65. 65.

    Mazzetti A, Moro L, Gerloni M, Cartwright M. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563.

    CAS  PubMed  Google Scholar 

  66. 66.

    A study to evaluate the safety and efficacy of CB-03-01 Cream, 1% in subjects with facial acne vulgaris (NCT02608450). https://clinicaltrials.gov/ct2/show/NCT02608450.Accessed 5 Jul 2019

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Maryanne M. Senna.

Ethics declarations

Funding

No funding was received for the conduct of this study or the preparation of this article.

Conflicts of Interest

Dr. Maryanne Senna is a member of the scientific advisory board of Cassiopea. Dustin H. Marks, Sonya Prasad, Brianna De Souza, and Laura J. Burns have no conflicts of interest to declare.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Marks, D.H., Prasad, S., De Souza, B. et al. Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris. Am J Clin Dermatol 21, 245–254 (2020). https://doi.org/10.1007/s40257-019-00493-z

Download citation